MolNFT v1 · #159704 · protein
X-ray crystal structure of wild type HIV-1 protease in complex with grl-004
6OYD: “X-ray crystal structure of wild type HIV-1 protease in complex with grl-004”. X-ray diffraction, 1 ligand (NKA), 2 pockets (best druggability 0.47). MolNFT v1 #159704 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 6OYD
- Type
- protein
- Length
- 99 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Protease
- UniProt
- Q8ULI2
- Ligands
- NKA
- Pockets
- 2 · best druggability 0.47
Structure
x-ray diffraction · 1 distinct chain · 4% helix, 49% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Protease | protein | 99 | 4% helix, 49% strand | Q8ULI2 |
Ligands and binding sites
- NKA · (3S,3aR,5R,7aS,8S)-hexahydro-4H-3,5-methanofuro[2,3-b]pyran-8-yl {(2S,3R)-1-(4-fluorophenyl)-3-hydroxy-4-[(2-methylpropyl)({2-[(propan-2-yl)amino]-1,3-benzoxazol-6-yl}sulfonyl)amino]butan-2-yl}carbamate · ligand · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
2 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 157 | 0.47 | 0.76 | 20 | empty |
| 2 | 80 | 0.31 | 0.73 | 19 | empty |
Compared structures
- 6OYD · X-ray crystal structure of wild type HIV-1 protease in complex with GRL-004 · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt Q8ULI2
- Elsewhere: RCSB PDB 6OYD · PDBe 6OYD · UniProt Q8ULI2
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.